Literature DB >> 27591578

Featured Article: Modulation of fetal hemoglobin in hereditary persistence of fetal hemoglobin deletion type-2, compared to Sicilian δβ-thalassemia, by BCL11A and SOX6-targeting microRNAs.

Thais A Fornari1, Carolina Lanaro1, Dulcinéia M Albuquerque1, Regiane Ferreira1, Fernando F Costa1.   

Abstract

Hereditary persistence of fetal hemoglobin deletion type-2 (HPFH-2) and Sicilian-δβ-thalassemia are conditions described as large deletions of the human β-like globin cluster, with absent β-globin chains and a compensatory variable increase in γ-globin. HPFH, in general, may be distinguished from DB-Thalassemia by higher fetal hemoglobin (HbF) levels, absence of anemia and hypochromic and microcytic erythrocytes. MicroRNAs (miRNAs) regulate a range of cellular processes including erythropoiesis and regulation of transcription factors such as the BCL11A and SOX6 genes, which are related to the regulation of γ-globin expression. In this report, a possible association among the overexpression of miRNAs and the expression of the γ-globin gene was analyzed in these two conditions. Forty-nine differentially expressed miRNAs were identified by microarrays in CD34+-derived erythroid cells of two subjects heterozygous for Sicilian-δβ-thalassemia, 2 for HPFH-2 and 3 for controls after 13 days of culture. Some of these miRNAs may participate in γ-globin gene regulation and red blood cell function. The BCL11A gene was found to be potentially targeted by 12 miRNAs that were up-regulated in HPFH-2 or in DB-Thal. A down-regulation of BCL11A gene expression in HPFH-2 was verified by quantitative polymerase chain reaction. These data suggest an important action for miRNA that may partially explain the phenotypic differences between HPFH-2 and Sicilian δβ-thalassemia and the increased expression of γ-globin in these conditions.

Entities:  

Keywords:  BCL11A; Hereditary persistence of fetal hemoglobin deletion type-2; SOX6; Sicilian-δβ-thalassemia; hemoglobinopathies; microRNAs

Mesh:

Substances:

Year:  2016        PMID: 27591578      PMCID: PMC5384494          DOI: 10.1177/1535370216668052

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  32 in total

Review 1.  Roles of hematopoietic transcription factors GATA-1 and GATA-2 in the development of red blood cell lineage.

Authors:  Kinuko Ohneda; Masayuki Yamamoto
Journal:  Acta Haematol       Date:  2002       Impact factor: 2.195

2.  Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A.

Authors:  Vijay G Sankaran; Tobias F Menne; Jian Xu; Thomas E Akie; Guillaume Lettre; Ben Van Handel; Hanna K A Mikkola; Joel N Hirschhorn; Alan B Cantor; Stuart H Orkin
Journal:  Science       Date:  2008-12-04       Impact factor: 47.728

Review 3.  An overview of molecular basis of iron metabolism regulation and the associated pathologies.

Authors:  Bruno Silva; Paula Faustino
Journal:  Biochim Biophys Acta       Date:  2015-04-02

4.  The switch from fetal to adult hemoglobin.

Authors:  Vijay G Sankaran; Stuart H Orkin
Journal:  Cold Spring Harb Perspect Med       Date:  2013-01-01       Impact factor: 6.915

5.  Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex.

Authors:  Marco Gabbianelli; Ugo Testa; Ornella Morsilli; Elvira Pelosi; Ernestina Saulle; Eleonora Petrucci; Germana Castelli; Serena Giovinazzi; Gualtiero Mariani; Micol E Fiori; Giuseppina Bonanno; Adriana Massa; Carlo M Croce; Laura Fontana; Cesare Peschle
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

6.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

7.  Developmental and species-divergent globin switching are driven by BCL11A.

Authors:  Vijay G Sankaran; Jian Xu; Tobias Ragoczy; Gregory C Ippolito; Carl R Walkley; Shanna D Maika; Yuko Fujiwara; Masafumi Ito; Mark Groudine; M A Bender; Philip W Tucker; Stuart H Orkin
Journal:  Nature       Date:  2009-08-05       Impact factor: 49.962

8.  Molecular identification of Sicilian (deltabeta) degrees-thalassemia associated with beta-thalassemia and hemoglobin S in Brazil.

Authors:  T G de Andrade; A Fattori; S T O Saad; M F Sonati; F F Costa
Journal:  Braz J Med Biol Res       Date:  2002-08       Impact factor: 2.590

9.  Molecular identification of hereditary persistence of fetal hemoglobin type 2 (HPFH type 2) in patients from Brazil.

Authors:  M S Gonçalves; S Fahel; M S Figueiredo; E J Kimura; F Nechtman; T A Stoming; V R Arruda; S T Saad; F F Costa
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

10.  Fluid Shear Stress Upregulates E-Tmod41 via miR-23b-3p and Contributes to F-Actin Cytoskeleton Remodeling during Erythropoiesis.

Authors:  Weiyun Mu; Xifu Wang; Xiaolan Zhang; Sida Zhu; Dagong Sun; Weibo Ka; Lanping Amy Sung; Weijuan Yao
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

View more
  4 in total

Review 1.  Omics Studies in Hemoglobinopathies.

Authors:  Eleni Katsantoni
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

2.  Disrupting the adult globin promoter alleviates promoter competition and reactivates fetal globin gene expression.

Authors:  Sarah K Topfer; Ruopeng Feng; Peng Huang; Lana C Ly; Gabriella E Martyn; Gerd A Blobel; Mitchell J Weiss; Kate G R Quinlan; Merlin Crossley
Journal:  Blood       Date:  2022-04-07       Impact factor: 22.113

Review 3.  Emerging roles of Sox6 in the renal and cardiovascular system.

Authors:  Mohammad Saleem; Pierina Barturen-Larrea; Jose A Gomez
Journal:  Physiol Rep       Date:  2020-11

Review 4.  Epigenetic Insights and Potential Modifiers as Therapeutic Targets in β-Thalassemia.

Authors:  Nur Atikah Zakaria; Md Asiful Islam; Wan Zaidah Abdullah; Rosnah Bahar; Abdul Aziz Mohamed Yusoff; Ridhwan Abdul Wahab; Shaharum Shamsuddin; Muhammad Farid Johan
Journal:  Biomolecules       Date:  2021-05-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.